|
NTI
Tension Suppression System
The most effective FDA-approved method of
migraine prevention
|
|
|
Below is a segment of
an article
appearing in the
January 2007 issue of
PRACTICAL Neurology.
Written by Stephen D. Silberstein, MD, it
describes the
current understanding of migraine pathophysiology.
Comments and insights
provided by
James P. Boyd, DDS appear in the right-side column
to further enhance the general dentist's
understanding of the NTI-tss' role in migraine prevention. |

|
Deepen Your Understanding of
Headache
By Stephen D.
Silberstein, MD
The current consensus is that
the term chronic daily
headache (CDH) refers to headache disorders experienced very frequently
(15 or
more days a month), including headaches associated with medication
overuse. CDH
can be divided into primary and secondary varieties.1
Studies in the
United
States, Europe and Asia suggest that four to five percent of the
general
population have primary CDH,2-4 and 0.5 percent have
severe headaches
daily.5-7
Once secondary headache,
including medication overuse
headache (MOH), has been excluded, frequent headache sufferers are
subdivided
into two groups, based on headache duration. When the duration is
greater than
four hours, the major primary disorders to consider are chronic
migraine (CM),
hemicrania continua (HC), chronic tension-type headache (CTTH) and new
daily
persistent headache (NDPH). CM, NDPH, and HC are primary CDH disorders
that are
now included in the 2nd IHS classification.8
Transformed migraine (TM)
is
similar, but not identical, to CM. Understanding and identifying the
multifarious presentations that fall under the rubric of CDH is further
complicated by its rather esoteric pathophysiology. In this article, we
will
look more closely at the mechanisms at work beneath the surface.
Pathophysiology Of
Chronic Daily Headache
The trigeminal nucleus caudalis
(TNC) of the trigeminal
complex, the major relay nucleus for head and face pain, receives
nociceptive
input from cephalic blood vessels and pericranial muscles (via the
trigeminal
and upper cervical nerves)A,
as well as inhibitory and facilitatory
suprasegmental input. The trigeminal nerve has three divisions:
ophthalmic,
mandibular and maxillary. Anterior pain-producing structures are
innervated by
the ophthalmic (first) division.B
Posterior regions are subserved by the
upper
cervical nerves.9
Afferent processes of the
trigeminal nerve converge to form
the sensory root, entering the brain stem at the pontine level and
terminating
in the trigeminal brain stem nuclear complex, which is composed of the
principal and the spinal trigeminal nuclei (subdivided into the nucleus
oralis,
the subnuclear interpolaris, and the nucleus caudalis). The brain stem
spinal
trigeminal nucleus is analogous to the dorsal horn of the spinal canal,
the
first synapse in the central nervous system.C
Most spinothalamic and
trigeminothalamic tract neurons that
originate from the dorsal horn and project to ventroposterior lateral
and
ventroposterior medial nuclei have wide dynamic-range
characteristics.10 The trigeminothalamic
tract is analogous to the spinothalamic tract. Second-order neurons
from the
trigeminal spinal nuclei form the trigeminothalamic tract and project
to other
midbrain structures, as well as to the thalamic tract. Most
ventroposterior
medial nuclei, some with wide dynamic-range characteristics, respond to
low-threshold stimuli.9 Recent evidence suggests that
central pain
facilitatory
neurons (on-cells) are present in the ventromedial medulla. In
addition,
neurons in the TNC can be sensitized as a result of intense neuronal
stimulation.
Pain has three spatiotemporal
characteristics: (1) as
intensity increases, the area in which it is experienced often enlarges
(radiation); (2) pain may outlast the evoking stimulus; and (3)
repeated nociceptive
stimuli D may increase
the perceived pain intensity, even without
increased input
(sensitization).11 Pain has both sensory and
affective dimensions. In
addition
to being physically unpleasant, pain is associated with negative
emotional
feelings shaped by context, anticipations and attitudes.10
Pain
unpleasantness
is in series with pain sensation intensity.
Headache
Pathophysiology
Pain in Migraine
Migraine most likely results from a dysfunction of
the
trigeminal nerveE
and
its central connections that normally modulate
sensory input. Components involved include: (1) the cranial blood
vessels and meninges; (2) the trigeminal innervation of the vessels and
meninges; (3) the reflex connections of the trigeminal system with the
cranial
parasympathetic outflow; and (4) local and descending pain modulation.F
The key
pathway for the pain is trigeminovascular input from the meningeal
vessels.
Brain imaging studies suggest that important modulation of the
trigeminovascular nociceptive input stems from the dorsal raphe
nucleus, locus
coeruleus and nucleus raphe magnus.12
Although the source of pain in
CDH is unknown and may depend
on the subtype, recent work suggests several mechanisms:
(1) increased peripheral
nociceptive activation (perhaps due
to chronic neurogenic inflammation) G
and
activation of silent
nociceptors; (2)
peripheral sensitization; (3) altered sensory neuron excitability due
to
changes in ion-channel expression/ phosphorylation/accumulation in
primary
afferents; (4) central sensitization of TNC neurons due to
posttranslational
changes in ligand- and voltage-gated ion-channel kinetics, altering
excitability and strength of their synaptic inputs; (5) phenotype
modulation
due to alterations in the expression of receptors/transmitters/ion
channels in
peripheral and central neurons; (6) synaptic reorganization
modification of
synaptic connections caused by cell death or sprouting; (7) decreased
pain
modulation due to loss of local and descending input;11
or (8) a
combination of
these.
Peripheral
Mechanisms
Although the brain itself is
largely insensate, pain can be
generated by large cranial vessels, proximal intracranial vessels or
dura
mater. The central convergence of the ophthalmic division of the
trigeminal
nerve and the branches of C2 nerve roots explain the typical
distribution of
migraine pain over the frontal and temporal regions and the referral of
pain to
the parietal, occipital and high cervical regions.12
During a migraine attack, an
inflammatory process occurs in
the meninges, at the site of the nerve terminal. Trigeminal nerve
activation is
accompanied by the release of vasoactive neuropeptides, including CGRP,
substance P (SP) and neurokinin A from the nerve terminals.H
These
mediators
produce mast cell activation, sensitization of the nerve terminals and
extravasation of fluid into the perivascular space around the dural
blood
vessels. Intense neuronal stimulation causes induction of c-fos (an
immediate early
gene product) in the TNC of the brainstem. SP and CGRP further amplify
the
trigeminal terminal sensitivity by stimulating the release of
bradykinin and
other inflammatory mediators from nonneuronal cells.13
Inflammatory
mediators increase the responsiveness of
and turn on silent, or sleeping, nociceptors. Neurotropins, such as
nerve
growth factor, are synthesized locally and can also activate mast cells
and
sensitive nerve terminals.14 Bradykinin and
kallidin, both acting
through the
B1 and B2 receptors, can activate primary afferent nociceptors.15
Prostaglandins
and nitric oxide (a diffusible gas that acts as a neurotransmitter)16
are both
endogenous mediators that can be produced locally and can sensitize
nociceptors. Cortical spreading depression (the cause of the aura) can
activate
the trigeminal system. I Repeated
episodes of neurogenic inflammation may
chronically sensitize the pain pathways and contribute to the
development of
daily headache.
Sarchielli et al.17
measured CSF
levels of nerve growth
factor (NGF), CGRP and SP in patients with TM both with and without
medication
overuse. Higher NGF, CGRP and SP levels were found in CSF in both
groups of
patients compared with controls. A correlation was found between NGF
and SP
levels. All levels correlated with the duration of the disorder. This
study
suggests the involvement of NGF and chronic activation of the
trigeminal
vascular system in TM. NGF production could arise from peripheral
trigeminal
nerve terminals as well as the TNC and pain facilitating pathways. A
study by
Ashina et al.18 strongly suggests that patients with
an elevated CGRP
level had
TM and that the trigeminal vascular system is activated as part of the
process of
TM.
<>Lance observed that during
migraine attacks patients
complain of increased pain with stimuli that would ordinarily be
non-nociceptive. These stimuli include hair-brushing, wearing a hat and
resting
the head on a pillow. This phenomenon of pain being produced by
non-painful
stimuli is referred to as allodynia. In a series of now-classic
experiments,
Burstein et al.19 explored allodynia development in
patients with
migraine. He
measured pain thresholds for hot, cold and pressure stimuli, both
within the
region of spontaneous pain and outside it. He found that as an attack
progressed in a selected group of migraine sufferers, cutaneous
allodynia
developed in the region of pain and then outside it (extracephalic
locations).
He found that 33 of 42 patients (79 percent) developed allodynia.
Allodynia
began over the first half of the attack in those who eventually
developed it.
Peripheral Sensitization.
Sensitization of nociceptors
results in an increased spontaneous neuronal discharge rate. Neurons
show
increased responsiveness to both painful and non-painful stimuli. The
receptor
fields expand and, as a result, pain is felt over a greater part of the
dermatome. This results in hyperalgesia (increased sensitivity to pain)
and
cutaneous allodynia. An example of this is sunburn, with increased
sensitivity
to temperature (i.e., a warm shower feels painfully hot).
How does sensitization occur?
Tissue injuryJ
and inflammation
result in the release of inflammatory mediators, such as prostaglandin
E2,
bradykinin and NGF. These substances act on G-protein-coupled receptors
or
tyrosine kinase receptors expressed on nociceptor terminals.K This
activates
intracellular signaling pathways, resulting in phosphorylation of
receptors and
ion channels. Phosphorylation changes the threshold and kinetics of the
nociceptor terminals, producing increased sensitivity and excitability
that results
in peripheral sensitization.20 Transcriptional or
translational
regulation can
also contribute to peripheral sensitization. NGF-induced activation of
p38
mitogen-activated protein kinase in primary sensory neurons after
peripheral
inflammation increases the expression and peripheral transport of TRPV1
(a
member of the transient receptor potential family), exacerbating heat
hyperalgesia.21
The normal rhythmic pulsation of
the meninges, which are
innervated by peripheral trigeminal neurons, can mediate the throbbing
pain
that migraineurs experience. With the increase in intracranial neuronal
sensitivity that migraine patients experience, the normal rhythmic
pulsation is
interpreted as painful. Bendtsen et al.22 has found
evidence for
sensitization
in CTTH patients. Pericranial myofascial tenderness, evaluated by
manual
palpation, was considerably higher in patients than in controls
(p<0.00001).
The stimulus-response function from highly tender muscle was
qualitatively
different than from normal muscle, suggesting that myofascial pain may
be
mediated by low-threshold mechanosensitive afferents projecting to
sensitized
dorsal horn neurons.L
|
A: pericranial muscles includes the
muscles of
mastication, whose pathologic contraction intensity can exceed
voluntary
maximum during sleep. Other trigeminally innervated structures,
such as the TM joint and periodontal ligaments also provide
considerable nociceptive input
B: The third division
innervates a large portion of
pain-producing structures as well
C: corresponding graphics on
on NTI website
D: which
includes the considerable noxious afferent activity created during
nocturnal trigeminally motor-innervated parafunction
E: both
sensory and motor dysfunction
F: excessive noxious
input from the
third division resulting from intense motor hyperactivity may also
influence normal sensory moduation
G: and perhaps due to excessive third division hyper motor
activity and resulting noxious activity
H: graphic
from MigrainePrevention.com
I: graphic
from MigrainePrevention.com
J:
perhaps
resulting from chronic nocturnal masticatory parafunction
K: therefore, a
therapeutic goal in the
prevention of migraine is to suppress the degree of trigeminal
nociception
L: and
possibly suggesing that myofascial pain and tenderness may be caused
and/or perpetuated by trigeminally innervated nocturnal hyper motor
activity
|
1. Silberstein SD, Lipton RB. Chronic daily headache
including
transformed migraine, chronic tension-type headache, and medication
overuse.
In: Silberstein SD, Lipton RB, Dalessio DJ, eds. Wolff's headache and
other
head pain, Seventh ed. New York: Oxford University Press, 2001:247-282.
2. Mathew NT, Stubits E, Nigam MR. Transformation of
episodic
migraine into daily headache: analysis of factors. Headache
1982;22:66-68.
3. Mathew NT, Reuveni U, Perez F. Transformed or
evolutive
migraine. Headache 1987;27:102-106.
4. Rapoport AM. Analgesic rebound headache. Headache
1988;28:662-665.
5. Scher AI, Stewart WF, Liberman J, Lipton RB.
Prevalence of
frequent headache in a population sample. Headache 1998;38:497-506.
6. Castillo J, Munoz P, Guitera V, Pascual J.
Epidemiology of
chronic daily headache in the general population. Headache
1999;39:190-196.
7. Wang SJ, Fuh JL, Lu SR, et al. Chronic daily headache
in
Chinese elderly: prevalence, risk factors and biannual follow-up.
Neurology
2000;54:314-319.
8. Headache Classification Committee. The International
Classification of Headache Disorders, 2nd Edition. Cephalalgia
2004;24:1-160.
9. Messlinger K, Burstein R. Anatomy of central nervous
system
pathways related to head pain. In: Olesen J, Tfelt-Hansen P, Welch KMA,
eds.
The headaches, 2nd ed. Philadelphia: Lippincott, Williams &
Wilkins,
1999:77.
10. Sweatt JD, Weeber EJ, Levenons JM. Central neural
mechanisms
that interrelate sensory and affective dimensions of pain. Mol Interven
2002;2:393-402.
11. Woolf CJ, Mitchell MB. Mechanism-based pain
diagnosis issues
for analgesic drug development. Anesthesiology 2001;95:241-249.
12. Goadsby PJ, Lipton RB, Ferrari MD. Migraine-current
understanding and treatment. N Engl J Med 2002 Jan 24;346:257-270.
13. Moskowitz MA. Basic mechanisms in vascular
headache. Neurol
Clin 1990;8:801-815.
14. Montalcini RL, Daltos R, Dellavalle F, et al.
Update of the
NGF saga. J Neurol Sci 1995;130:119-127.
15. Rang HP, Urban L. New molecules in analgesia. Br J
Anaesth
1995;75:145-156.
16. Edelman GM, Gally JA. Nitric oxide: linking space
and time
in the brain. Proc Natl Acad Sci USA 1992;89:1165111652.
17. Sarchielli P, Alberti A, Floridi A, Gallai V.
Levels of
nerve growth factor in cerebrospinal fluid of chronic daily headache
patients.
Neurology 2001 Jul 10;57:132-134.
18. Ashina M, Bendtsen L, Jensen R, Schifter S,
Jansen-Olesen I,
Olesen J. Plasma levels of calcitonin gene-related peptide in chronic
tension-type headache. Neurology 2000;55:1335-1340.
19. Burstein R, Yarnitsky D, Goor-Aryeh I, Ransil BJ,
Bajwa ZH.
An association between migraine and cutaneous allodynia. Ann Neurol
2000;47:614-624.
20. Julius D, Basbaum AI. Molecular mechanisms of
nociception.
Nature 2001 Sep 13;413:203-210.
21. Ji RR, Samad TA, Jin SX, Schmoll R, Woolf CJ. p38
MAPK
activation by NGF in primary sensory neurons after inflammation
increases TRPV1
levels and maintains heat hyperalgesia. Neuron 2002 Sep 26;36:57-68.
22. Bendtsen L, Jensen R, Olesen
J. Qualitatively altered
nociception in chronic myofascial pain. Pain 1996;65:259-264.
|